PeptideDB

hFSH-β-(33-53) (TFA)

hFSH-β-(33-53) (TFA)

CAS No.:

hFSH-β-(33-53) TFA is a thiol-containing peptide corresponding to the second FSH receptor-binding domain and is an FSHR
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

hFSH-β-(33-53) TFA is a thiol-containing peptide corresponding to the second FSH receptor-binding domain and is an FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits/disrupts the binding of FSH to the receptor and is a partial agonist of estradiol synthesis in Sertoli cells.

Physicochemical Properties


Molecular Formula C115H183N31O32S.XC2HF3O2
Molecular Weight 2543.94 (free acid)
Appearance Solid powder
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


References

[1]. A synthetic peptide corresponding to hFSH-beta-(81-95) has thioredoxin-like activity. Mol Cell Endocrinol. 1991;78(3):163-170.

[2]. Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging. Mol Imaging Biol. 2014;16(4):578-585.

[3]. Serine analogues of hFSH-beta-(33-53) and hFSH-beta-(81-95) inhibit hFSH binding to receptor. Biochem Biophys Res Commun. 1992;184(3):1273-1279.


Solubility Data


Solubility (In Vitro) DMSO :~100 mg/mL
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)